CRDL News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$133.4M

Volume

559.23K

Next Earnings

November 12th

Mkt Cap

$139.7M

Volume

559.23K

Next Earnings

November 12th

Chart Earnings News About Insider Filings

Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsightOver 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.GlobeNewswire Inc. · Oct 13, 2026

5 Small Drug Stocks to Buy From a Recovering IndustryInnovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.Zacks Investment Research · May 24, 2024

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs InRoy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharmaceutical applications and a diversification of medical cannabis products. Bingham notes that the rescheduling will be a game-changer for research, allowing scientists to pursue careers studying cannabinoids without risking their careers. "For the last 50 years, studying cannabinoids was a career ender for young scientists. Now, they will be able to pursue it and come up with fascinating discoveries." Economic And Operational Impacts The rescheduling is likely to alleviate financial pressures on cannabis businesses, notably by eliminating certain tax burdens, which Bingham says will "inject much more cash and capital into the industry." This financial liberation is expected to accelerate research and development, particularly in medical cannabis, potentially attracting substantial investment from healthcare and pharmaceutical companies. He also anticipates ...Full story available on Benzinga.comBenzinga · May 14, 2024

Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move.Zacks Investment Research · Sep 27, 2023

Here's Why You May Invest in Cardiol Therapeutics (CRDL) StockHere we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move.Zacks Investment Research · Sep 27, 2023

Why Murphy Canyon Acquisition Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving PremarketGainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer. Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 28.5% to $5.03 in pre-market trading after falling 11% on Wednesday. Neptune Wellness announced intention to spinout Sprout Organics pursuant to the Morgan Stanley agreed to transaction. Murphy Canyon Acquisition Corp. (NASDAQ: MURF) shares rose 32.4% to $17.00 in pre-market trading. Murphy Canyon Acquisition reported stockholder approval of the proposed combination with Conduit Pharmaceuticals. TradeUP Acquisition Corp. (NASDAQ: UPTD) shares jumped 24.2% to $15.22 in pre-market trading after surging 26% on Wednesday. The company announced an extension for its initial business combination deadline, depositing an aggregate of $37,432.70 into its trust account. Alliance Entertainment Holding Corporation (NASDAQ: AENT) shares gained 19.8% to $1.27 in pre-market trading after falling ...Benzinga · Sep 21, 2023

Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?Here is how Cardiol Therapeutics Inc. (CRDL) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.Zacks Investment Research · Sep 19, 2023

Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol TherapeuticsCorcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics are part of the Zacks Industry Outlook article.Zacks Investment Research · Sep 19, 2023

5 Stocks to Buy as Drug Industry Displays Strong FundamentalsInnovation is expected to continue driving growth in the Medical-Drugs industry. CORT, AUPH, ALPN, KALV and CRDL may prove to be good additions to one's portfolio.Zacks Investment Research · Sep 18, 2023

Cardiol Therapeutics Inc. (CRDL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?After losing some value lately, a hammer chart pattern has been formed for Cardiol Therapeutics Inc. (CRDL), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.Zacks Investment Research · Sep 13, 2023

CRDLCardiol Therapeutics Inc. Class A Common Shares

CRDL

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any CRDL yet.

Related Tickers

Earnings

Mkt Cap

$133.4M

Volume

559.23K

Next Earnings

November 12th